Structural biology of SARS-CoV-2 and implications for therapeutic development
H Yang, Z Rao - Nature Reviews Microbiology, 2021 - nature.com
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), is an unprecedented global health crisis. However, therapeutic options for …
(SARS-CoV-2), is an unprecedented global health crisis. However, therapeutic options for …
Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment
S Boopathi, AB Poma, P Kolandaivel - Journal of Biomolecular …, 2021 - Taylor & Francis
In the past two decades, the world has faced several infectious disease outbreaks. Ebola,
Influenza A (H1N1), SARS, MERS, and Zika virus have had a massive global impact in terms …
Influenza A (H1N1), SARS, MERS, and Zika virus have had a massive global impact in terms …
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been
demonstrated to be clinically useful against COVID-19 (refs.,). However, because SARS …
demonstrated to be clinically useful against COVID-19 (refs.,). However, because SARS …
SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376
Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first
protease inhibitor specifically developed against the SARS-CoV-2 protease 3CLpro that has …
protease inhibitor specifically developed against the SARS-CoV-2 protease 3CLpro that has …
[HTML][HTML] Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
A new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), is the aetiological agent responsible for the 2019–2020 viral pneumonia outbreak of …
2), is the aetiological agent responsible for the 2019–2020 viral pneumonia outbreak of …
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
A new coronavirus SARS-CoV-2, also called novel coronavirus 2019 (2019-nCoV), started
to circulate among humans around December 2019, and it is now widespread as a global …
to circulate among humans around December 2019, and it is now widespread as a global …
Structural basis of potential inhibitors targeting SARS-CoV-2 main protease
The Coronavirus disease-19 (COVID-19) pandemic is still devastating the world causing
significant social, economic, and political chaos. Corresponding to the absence of globally …
significant social, economic, and political chaos. Corresponding to the absence of globally …
The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19
Q Hu, Y Xiong, GH Zhu, YN Zhang, YW Zhang… - MedComm, 2022 - Wiley Online Library
The main proteases (Mpro), also termed 3‐chymotrypsin‐like proteases (3CLpro), are a
class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has …
class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has …
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
A Douangamath, D Fearon, P Gehrtz, T Krojer… - Nature …, 2020 - nature.com
Abstract COVID-19, caused by SARS-CoV-2, lacks effective therapeutics. Additionally, no
antiviral drugs or vaccines were developed against the closely related coronavirus, SARS …
antiviral drugs or vaccines were developed against the closely related coronavirus, SARS …
[HTML][HTML] Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines
X Liu, XJ Wang - Journal of Genetics and Genomics, 2020 - ncbi.nlm.nih.gov
Coronaviruses, members of the family Coronaviridae and subfamily Coronavirinae, are
enveloped positive-strand RNA viruses which have spikes of glycoproteins projecting from …
enveloped positive-strand RNA viruses which have spikes of glycoproteins projecting from …